A Global Approach To Medtech Regulation: The Post-EU Way Ahead For UK Industry?
As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.
You may also be interested in...
Parliamentary committee meetings on the UK’s devices bill have been postponed as measures to tackle COVID-19 have been moved to center stage.
Securing a favorable post-Brexit free trade agreement with the US is the principal aim of the UK’s Department for International Trade, and the UK medtech industry is pressing its case for closer business links with its largest non-EU trading partner.
With the obvious distractions of coronavirus, the UK Medicines and Medical Devices bill has entered its second reading in parliament, accompanied by a drive for it to succeed from the government and opposition parties.